

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

KING DRUG COMPANY OF FLORENCE, INC., <u>et al.</u> , Plaintiffs, v. CEPHALON, INC., <u>et al.</u> , Defendants.	:	CIVIL ACTION No. 2:06-cv-1797
VISTA HEALTHPLAN, INC., <u>et al.</u> , Plaintiffs, v. CEPHALON, INC., <u>et al.</u> , Defendants.	:	CIVIL ACTION No. 2:06-cv-1833
APOTEX, INC., Plaintiff, v. CEPHALON, INC., <u>et al.</u> , Defendants.	:	CIVIL ACTION No. 2:06-cv-2768
FEDERAL TRADE COMMISSION, Plaintiff, v. CEPHALON, INC., Defendant.	:	CIVIL ACTION No. 2:08-cv-2141

ORDER

AND NOW, this 28th day of January, 2015, upon consideration of “Defendants Cephalon, Barr, and Teva’s Motion for Summary Judgment on Plaintiffs’ Challenges to the Settlement Agreements” (Dkt. No. 06-1797, Doc. No. 626; Dkt. No. 06-1833, Doc. No. 307; Dkt. No. 06-2768, Doc. No. 710; Dkt. No. 08-2141, Doc. No. 275), “Motion of the Mylan Defendants’ for Summary Judgment on All Claims Under FTC v. Actavis” (Dkt. No. 06-1797, Doc. No. 612; Dkt. No. 06-1833, Doc. No. 295; Dkt. No. 06-2768, Doc. No. 690), and “Ranbaxy Defendants’ Motion for Summary Judgment” (Dkt. No. 06-1797, Doc. No. 621; Dkt. No. 06-1833, Doc. No. 302; Dkt. No. 06-2768, Doc. No. 702), and following oral argument, and for the reasons stated in the accompanying memorandum opinion, it is hereby **ORDERED** that these motions are **DENIED**.

BY THE COURT:

/s/ Mitchell S. Goldberg

Mitchell S. Goldberg, J.